Navigation Links
Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer

WAILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced preliminary results from two open-label, multi-center Phase 2 clinical trials supporting the potential use of Xcytrin(R) (motexafin gadolinium) Injection, the company's lead product candidate, in combination with Alimta(R) (pemetrexed) and in combination with Taxotere(R) (docetaxel) as a second-line treatment for patients with non-small cell lung cancer (NSCLC) who failed at least one platinum-based chemotherapy regimen. The results were presented today at the Eighth International Lung Cancer Congress in Wailea, Hawaii.

The first ongoing study is evaluating Xcytrin plus Alimta and has enrolled 27 patients of which 20 are evaluable for response at this time. Patients are receiving 15mg/kg Xcytrin with a standard dose of Alimta and treatment is repeated every 21 days. Seventeen patients (85%) receiving Xcytrin and Alimta have achieved stabilization of their tumors, with 10 of the 17 still on treatment for up to nine cycles. The median survival time and median time to progression have not been reached, with estimated actuarial survival of 69% at 12 months. Patients still on treatment remain under evaluation for tumor response. The most common severe (Grade 3 or higher) side effects were asthenia (10.3%), pneumonia (10.3%), thrombocytopenia (10.3%), and neutropenia (6.9%).

The other ongoing study is evaluating Xcytrin plus Taxotere and has enrolled 24 patients of which 14 are evaluable for response at this time. Patients are given 15mg/kg Xcytrin with a standard dose of Taxotere and treatment is repeated every 21 days. Thirteen patients (87%) receiving Xcytrin and Taxotere have achieved stabilization of their tumors, with four still on treatment. The median survival time is 8.2 months and the median time to progression is 8.7 months. Patients still on treatment remain under evaluation for
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:9/19/2014)... , Sept. 19, 2014 Research and ... Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market ... For the purposes of this report, the human microbiome ... The human microbiome market is expected to be valued ... at a CAGR of 22.3% within the forecast period of ...
(Date:9/19/2014)... Sept. 19, 2014  Diplomat, the nation,s largest independent ... Dreyer to the Board of Directors on September ... will also serve as chair of the Audit Committee. ... of accounting, financial, compliance and operating experience in the ... served as chief financial officer, chief operating officer and ...
(Date:9/19/2014)... Larry J. Merlo , President and CEO ... before the National Press Club in Washington, D.C. ... to stop selling tobacco products and its leadership in driving ... "Dramatic changes in our health care system pose enormous ... has said. "CVS Health has a truly unique combination of ...
Breaking Medicine Technology:Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3David Dreyer Appointed to Diplomat Board of Directors 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3
... (Nasdaq: PRGO; TASE) today announced that it has signed ... assets of Paddock Laboratories, Inc. ("Paddock"), a privately-held, Minneapolis-based ... $540 million in cash. Perrigo expects to receive a ... of Paddock,s assets. The net present value of this ...
... MIAMI, Jan. 20, 2011 CyberKnife Center of ... Schwade, MD, FACR, FACRO, FASTRO, announces a presentation ... 38th Annual Caribbean Association of Neurosurgeon,s Annual Meeting, ... (Photo: http://photos.prnewswire.com/prnh/20110120/FL32893 ) ...
Cached Medicine Technology:Perrigo to Acquire Assets of Paddock Labs for $540 Million 2Perrigo to Acquire Assets of Paddock Labs for $540 Million 3Perrigo to Acquire Assets of Paddock Labs for $540 Million 4Perrigo to Acquire Assets of Paddock Labs for $540 Million 5CyberKnife Center of Miami to Present at 38th Annual Caribbean Association of Neurosurgeon's Conference 2
(Date:9/19/2014)... News) -- U.S. military troops deployed to sunny climates ... to a new study. Many returning troops ... some cases, military personnel developed blisters on their skin ... size of their moles since being deployed overseas. ... skin cancer, the study authors noted. "The past ...
(Date:9/19/2014)... News) -- Pregnant women who live in leafy, green neighborhoods ... babies, a new study suggests. Researchers analyzed data from ... expectant mothers who lived in a neighborhood with plenty of ... risk of very preterm birth (before 30 weeks) and a ... 36 weeks). Babies born to mothers who lived in ...
(Date:9/19/2014)... The U.S. Food and Drug Administration approved a new type ... a class of once-a-week injectable drugs that help manage blood ... "Trulicity is a new treatment option, which can be used ... sugar levels in the overall management of type 2 diabetes," ... Drug Evaluation II, said in an agency news release. ...
(Date:9/19/2014)... 2014 The Alliance for Bangladesh ... the National Fire Protection Association (NFPA), a recognized ... today in a Memorandum of Understanding signed by ... and other stakeholders with information, guidance and access ... health and safety of workers in ready-made garment ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 MetroMD, a leading ... the “God Particle” of human health. This therapy has grown ... making the therapy more effective, safe and dependable. It has ... them an opportunity to live a very healthy and active ... concept of HGH therapy, a senior therapist at MetroMD said, ...
Breaking Medicine News(10 mins):Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 3Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2
... , FRIDAY, July 15 (HealthDay News) -- In an attempt ... of governments have raised taxes on cigarettes, yet many people ... Canadian study. But the public health measure has prompted ... researchers recently reported in the International Journal of Environmental ...
... In a study, Identification of unrecognized diabetes and pre-diabetes ... issue of the Journal of Dental Research, ... that dental visits represented a chance to intervene in ... pre-diabetes who are unaware of their condition. The study ...
... sizes usually mean we eat more food, but according to ... bigger bites lead to eating lessin restaurant settings. "In ... bite-sizes on overall quantity of food consumed," write authors Arul ... Utah, Salt Lake City). The authors conducted a field ...
... HealthDay Reporter , THURSDAY, July 14 (HealthDay News) -- ... the immune system,s response to HIV, the AIDS virus, in ... a vaccine. The findings won,t have an immediate big ... do reveal how soldiers of the immune system known as ...
... five to ten percent of patients with primary ... such as headaches, seizures, confusion, difficulty swallowing and ... life-threatening form of brain invasion from cancer called ... University of California, San Diego School of Medicine ...
... This release is available in German . ... Max Planck Institute for Dynamics and Self-Organization (Gttingen, Germany), ... de Lyon (France), the University Medicine Gttingen (Germany), the ... de Nice (France) have developed a new low-energy method ...
Cached Medicine News:Health News:Cigarette Tax Unlikely to Deter Some Smokers: Report 2Health News:Dentists can identify people with undiagnosed diabetes, Columbia researchers show 2Health News:Size matters: Why do people eat less when they have big forks? 2Health News:Antibody Finding Might Help in Search for HIV Vaccine 2Health News:Novel combined therapy extends life, diminishes pain in brain cancer patients 2Health News:A 'LEAP' in controlling cardiac fibrillation 2Health News:A 'LEAP' in controlling cardiac fibrillation 3
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
Medicine Products: